CPGJ888 - 博客园

2015年7月1日

摘要：基线MRI与CRP是依那西普对nr-axSpA的疗效预测因素EULAR2015; PresentID:SAT0258 BASELINE MRI/CRP AS PREDICTORS OF RESPONSETO ETANERCEPT IN THE MANAGEMENT OF PATIENTS W... 阅读全文

posted @ 2015-07-01 03:08 CPGJ888 阅读(418) 评论(0) 推荐(0)

axSpA患者新发炎症更容易发生在既往发生过炎症的区域

摘要： axSpA患者新发炎症更容易发生在既往发生过炎症的区域EULAR2015;PresentID: SAT0240 NEWINFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS ARE MORE LIKELY TOOCCUR IN THE AREAS A... 阅读全文

posted @ 2015-07-01 02:59 CPGJ888 阅读(443) 评论(0) 推荐(0)

NSAIDs以优化剂量治疗中轴型SpA：聚焦6周期间骶髂关节MRI变化

摘要： NSAIDs以优化剂量治疗中轴型SpA：聚焦6周期间骶髂关节MRI变化PresentID:OP0170 TREATMENT OF AXIALSPONDYLOARTHRITIS WITH AN OPTIMAL DOSAGE OF NSAIDS: A 6-WEEK FOLLOWUP STUDY F... 阅读全文

posted @ 2015-07-01 02:48 CPGJ888 阅读(405) 评论(0) 推荐(0)

MRI炎症和结构损伤指标对TNF拮抗剂治疗AS患者获持续缓解的预测价值

摘要： MRI炎症和结构损伤指标对TNF拮抗剂治疗AS患者获持续缓解的预测价值EULAR2015; PresentID:OP0043PREDICTORS OF SUSTAINEDREMISSION ON ANTI-TNF IN AN OBSERVATIONAL COHORT OF PATIENTS W... 阅读全文

posted @ 2015-07-01 02:34 CPGJ888 阅读(265) 评论(0) 推荐(0)

ASAS-CoMoSpA研究: 评价SpA不同分类标准的表现

摘要： ASAS-CoMoSpA研究:评价SpA不同分类标准的表现 EULAR2015; PresentID:OP0037THE PERFORMANCE OFDIFFERENT CLASSIFICATION CRITERIA SETS FOR SPONDYLOARTHRITIS IN THEASAS-... 阅读全文

posted @ 2015-07-01 02:08 CPGJ888 阅读(477) 评论(0) 推荐(0)

DESIR队列：早期axSpA的脊柱放射学进展

摘要： DESIR队列：早期axSpA的脊柱放射学进展EULAR2015; PresentID:FRI0234SPINALRADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS: DATAFROM THE DESIR COHORTS.Rami... 阅读全文

posted @ 2015-07-01 01:57 CPGJ888 阅读(610) 评论(0) 推荐(0)

早期SpA患者髋关节的受累发生率

摘要：早期SpA患者髋关节的受累发生率EULAR2015,PresentID: FRI0236 原文译文How often are hip joints involved in patientswith early spondyloarthritis?T. Dubinina1,*,E. Gubar1... 阅读全文

posted @ 2015-07-01 01:39 CPGJ888 阅读(520) 评论(0) 推荐(0)

2015年6月30日

依那西普治疗多关节型和系统型JRA的长期疗效[EULAR2007_SAT0397]

摘要：依那西普治疗多关节型和系统型JRA的长期疗效Giannini EH, Ilowite NT. EULAR2007. Abstract No:SAT0397.标签: EULAR2007，EULAR文摘，依那西普，幼年特发性关节炎，长期疗效，中信国健临床通讯方法：为期3年开放性、非随机的注册资料包括了2～18岁的多关节型和系统型幼年类风湿关节炎(JRA)。单用MTX或依那西普(ETN), 或着两者... 阅读全文

posted @ 2015-06-30 18:35 CPGJ888 阅读(367) 评论(0) 推荐(0)

随时代变迁而进化的治疗策略不断提高RA无药缓解机会[EULAR2015_SAT0058]

摘要：随时代变迁而进化的治疗策略不断提高RA无药缓解机会 SAT0058DMARD-FREE SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS: AN OUTCOME ASSOCIATED WITH SUBSIDENCE OF SYMPTOMS THAT IS INCREASINGLY ACHIEVED WITH IMPROVED TREATMENT STRATEG... 阅读全文

posted @ 2015-06-30 16:59 CPGJ888 阅读(189) 评论(0) 推荐(0)

常规诊疗条件下比较依那西普生物类似药(益赛普)与阿达木、英夫利西对RA的疗效[EULAR2015_SAT0360]

摘要：常规诊疗条件下比较依那西普生物类似药（益赛普）与阿达木单抗、英夫利西单抗治疗RA的临床疗效 SAT0360ETANAR - A ETANERCEPT BIOSIMILAR IS AS EFFECTIVE ASADALIMUMAB AND INFLIXIMAB IN A COHORT OF RE... 阅读全文

posted @ 2015-06-30 15:39 CPGJ888 阅读(2910) 评论(0) 推荐(0)

公告